Jaya Mallidi1, Kusum Lata2. 1. Division of Cardiology, Santa Rosa Memorial Hospital, 500 Doyle Park Drive, Suite G05, Santa Rosa, CA, 95405, USA. jaya.mallidi@gmail.com. 2. Division of Cardiology, Sutter Gould Medical Foundation, Stockton, CA, USA.
Abstract
PURPOSE OF REVIEW: The effect of gender on use of dual antiplatelet therapy (DAPT) in treatment of acute coronary syndrome (ACS) is not well established. The purpose of this review is to understand gender-based differences in response to DAPT, so that treatment of ACS can be optimized in women to prevent ischemic events while minimizing bleeding risk. RECENT FINDINGS: There are innate gender differences in platelet reactivity and response. However, it is unknown if this translates into differences in clinical outcomes. In all major studies evaluating the effect of DAPT in ACS, women are underrepresented. Hence, the results from the existing trials cannot be generalizable to women. There is a significant knowledge gap regarding how to balance the bleeding and ischemic risk profile among women with ACS. Currently, there is no recommendation to consider gender as covariate in choosing the type of antiplatelet drug or duration. The existing clinical evidence is limited by under representation of women in DAPT trials. The current literature does not strongly support considering gender in decision making regarding type or duration of DAPT after ACS. Future dedicated trial designs with adequate representation from women and gender specific analysis from large registry data are warranted to enhance our understanding of the interaction of gender with DAPT after ACS.
PURPOSE OF REVIEW: The effect of gender on use of dual antiplatelet therapy (DAPT) in treatment of acute coronary syndrome (ACS) is not well established. The purpose of this review is to understand gender-based differences in response to DAPT, so that treatment of ACS can be optimized in women to prevent ischemic events while minimizing bleeding risk. RECENT FINDINGS: There are innate gender differences in platelet reactivity and response. However, it is unknown if this translates into differences in clinical outcomes. In all major studies evaluating the effect of DAPT in ACS, women are underrepresented. Hence, the results from the existing trials cannot be generalizable to women. There is a significant knowledge gap regarding how to balance the bleeding and ischemic risk profile among women with ACS. Currently, there is no recommendation to consider gender as covariate in choosing the type of antiplatelet drug or duration. The existing clinical evidence is limited by under representation of women in DAPT trials. The current literature does not strongly support considering gender in decision making regarding type or duration of DAPT after ACS. Future dedicated trial designs with adequate representation from women and gender specific analysis from large registry data are warranted to enhance our understanding of the interaction of gender with DAPT after ACS.
Authors: Karen L Margolis; JoAnn E Manson; Philip Greenland; Rebecca J Rodabough; Paul F Bray; Monika Safford; Richard H Grimm; Barbara V Howard; Annlouise R Assaf; Ross Prentice Journal: Arch Intern Med Date: 2005-03-14
Authors: Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Karen P Alexander; Anita Y Chen; L Kristin Newby; Janice B Schwartz; Rita F Redberg; Judith S Hochman; Matthew T Roe; W Brian Gibler; E Magnus Ohman; Eric D Peterson Journal: Circulation Date: 2006-09-18 Impact factor: 29.690
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Diane M Becker; Jodi Segal; Dhananjay Vaidya; Lisa R Yanek; J Enrique Herrera-Galeano; Paul F Bray; Taryn F Moy; Lewis C Becker; Nauder Faraday Journal: JAMA Date: 2006-03-22 Impact factor: 56.272
Authors: Karla Kurrelmeyer; Lewis Becker; Diane Becker; Lisa Yanek; Pascal Goldschmidt-Clermont; Paul F Bray Journal: J Am Med Womens Assoc (1972) Date: 2003